Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
MD

NASDAQ · MDCXW

Medicus Pharma Ltd.

Healthcare · Biotechnology

$0.29

Down-$0.01 (-3.33%)

Updated Oct 11, 2026, 1:00 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
22.92M
P/E ratio
-2.65
Dividend yield
0.00%
52-week range
$0.01 – $1.45
Volume
2.46K
Avg. volume
6.01K

Price performance · MDCXW

MDCXW price history

1M range · 6 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

MDCXW closed at $0.29 after 6 trading sessions, down 9.83% for the selected period.

Last close
$0.29
Period change
-9.83%
Period low
$0.29
Period high
$0.36
Daily close
View OHLC price history
MDCXW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$0.3405$0.365$0.0111$0.292.46K
Oct 6, 2026$0.3001$0.3026$0.30$0.304.43K
Sep 29, 2026$0.30$0.30$0.30$0.30220
Sep 23, 2026$0.31$0.3105$0.31$0.311.42K
Sep 22, 2026$0.31$0.355$0.31$0.3552.21K
Sep 15, 2026$0.44$0.44$0.3216$0.3216863.51

Latest MDCXW news

The latest Smart Investors Daily articles mentioning MDCXW.

Stock researchCompany · Overview

MDCXW research

Overview

Company profile and research snapshot.

Company profile

Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing

Medicus Pharma is prioritizing clinical milestones, regulatory progress and potential partnerships across its oncology, dermatology and urology portfolio as it seeks to demonstrate returns on three years of investment. Key Investor TakeawaysMedicus Pharma (NASDAQ:MDCX) has raised approximately $90 million through equity and debt financing over three years, supporting acquisitions, clinical development and operations.

Yahoo · Oct 8, 2026

Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value

Advancing Precision Oncology and Partner-Ready Therapeutic Programs Through Capital-Efficient DevelopmentPHILADELPHIA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today provided a shareholder update celebrating its third anniversary, highlighting three years of progress, focused on execution and capital efficient drug d

Yahoo · Oct 5, 2026

Medicus Pharma seeks FDA alignment on streamlined Phase 2b/3 Teverelix study

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss the company’s submission of an optimized seamless Phase 2b/3 registration-intent protocol to the U.S. Food and Drug Administration (FDA) for Teverelix®, its investigational next-generation, long-acting GnRH antagonist being developed for patients with advanced prostate cancer (APC) who are at increased cardiovascular risk. Bokhari explained that the proposed protocol is designed to establish a defined and potentially more capital-efficient pathway toward registration while positioning the Teverelix APC program for a potential strategic partnership. Importantly, Medicus does not intend to independently fund an additional clinical development study in the APC program at this time. The proposed study design is stage-gated and would begin with approximately 80 randomized patients. This initial stage is designed to incorporate and replace the previously FDA-cleared standalone 40-patient open-label Phase 2b dose-optimization study predefined continuation criteria before potentially expanding into a larger registration-intent stage. If those criteria are met, approximately 528 additional patients would be enrolled, bringing the planned total to approximately 608 participants. Medicus believes that, if accepted by the FDA, the proposed design could substantially reduce the overall size of the planned clinical development program. The company previously contemplated a program involving approximately 1,500 patients; the optimized design could reduce that figure to approximately 600 patients. The proposed pathway is intended to address several objectives within a single clinical program, including dose optimization, androgen suppression and prospective evaluation of potential cardiovascular differentiation in advanced prostate cancer patients who have elevated cardiovascular risk. Following FDA feedback, and depending on the nature of that feedback, Medicus intends to seek an out-licensing transaction or another strategic partnership for the Teverelix APC program rather than independently financing execution of the proposed registrational study. If the FDA agrees that the proposed approach could support a registration pathway, Medicus believes the design could provide a shorter and more capital-efficient route than the previously contemplated sequential clinical development program. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Teverelix #ProstateCancer #CancerResearch #Oncology #Biopharma #ClinicalTrials #FDA #DrugDevelopment #GnRH #AndrogenSuppression #CardiovascularRisk #Phase2 #Phase3 #ClinicalResearch #Healthcare #LifeSciences #Biotechnology

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By